Cargando…
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework
The objectives of the study were to use tumor size data from 10 phase II/III atezolizumab studies across five solid tumor types to estimate tumor growth inhibition (TGI) metrics and assess the impact of TGI metrics and baseline prognostic factors on overall survival (OS) for each tumor type. TGI met...
Autores principales: | Chan, Phyllis, Marchand, Mathilde, Yoshida, Kenta, Vadhavkar, Shweta, Wang, Nina, Lin, Alyse, Wu, Benjamin, Ballinger, Marcus, Sternheim, Nitzan, Jin, Jin Y., Bruno, René |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520743/ https://www.ncbi.nlm.nih.gov/pubmed/34270868 http://dx.doi.org/10.1002/psp4.12686 |
Ejemplares similares
-
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
por: Wu, Benjamin, et al.
Publicado: (2021) -
Application of Machine Learning for Tumor Growth Inhibition – Overall Survival Modeling Platform
por: Chan, Phyllis, et al.
Publicado: (2020) -
External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data
por: Kassir, Nastya, et al.
Publicado: (2023) -
Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time
por: Netterberg, Ida, et al.
Publicado: (2020) -
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)
por: Peters, Solange, et al.
Publicado: (2021)